Executive Employment Agreement, effective as of January 25, 2025, by and between Daniel Gordon Kirby and Iovance Biotherapeutics, Inc
Exhibit 10.43
Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed or constitutes personal information. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
EXECUTIVE EMPLOYMENT AGREEMENT
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 25, 2025 by and between Iovance Biotherapeutics, Inc., a Delaware corporation (the “Company”), and Daniel Gordon Kirby (“Employee”) (either party individually, a “Party”; collectively, the “Parties”).
WHEREAS, the Company desires to employ Employee to serve in the position as set forth below;
WHEREAS, the Parties desire to enter into this Agreement to set forth the terms and conditions of Employee’s employment by the Company and to address certain matters related to Employee’s employment with the Company;
WHEREAS, both the Company and the Employee have read and understood the terms and provisions set forth in this Agreement, and Employee acknowledges Employee has been afforded a reasonable opportunity to review this Agreement with Employee’s legal counsel to the extent desired;
NOW, THEREFORE, in consideration of the foregoing, the promises and obligations set forth below and for other good and valuable consideration, the receipt of which is hereby acknowledged by the Parties, the Company and Employee agree and intend to be legally bound, as follows:
2
For avoidance of doubt, the Signing Bonus Payment is an advance only and shall not be deemed earned unless the foregoing requirements for the Signing Bonus Payment are satisfied.
3
4
5
6
7
8
[Execution Page Follows]
9
THE PARTIES TO THIS AGREEMENT HAVE READ THE FOREGOING AGREEMENT AND FULLY UNDERSTAND EACH AND EVERY PROVISION CONTAINED HEREIN. WHEREFORE, THE PARTIES HAVE EXECUTED THIS AGREEMENT AS SHOWN BELOW.
| EMPLOYEE: Daniel Gordon Kirby /s/ Daniel G. Kirby Date: January 27, 2025 [***] COMPANY: Iovance Biotherapeutics, Inc. By: /s/ Frederick G. Vogt Date: January 27, 2025 Name: Frederick Vogt, Ph.D., J.D. Title: Interim Chief Executive Officer and President, and General Counsel 825 Industrial Road, Suite 100 San Carlos, California 94070 |
10
Exhibit A
PSUs
11